bnt327
mAbexperimentalBi-specific
Clinical trial activity
19 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
16
Phase 3
5
Phase 4
0
Earliest trial started Aug 5, 2024 (NCT06449209)
Timeline
Indications
Mechanism of action
- Vascular endothelial growth factor AINHIBITOR
VEGFA inhibitor
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07293351 | Phase 1/Phase 2 (Phase 2) | Mar 26, 2026 | Biontech, Bristol-Myers Squibb |
| NCT07221149 | Phase 2/Phase 3 (Phase 3) | Mar 9, 2026 | Biontech, Bristol-Myers Squibb |
| NCT07221357 | Phase 2/Phase 3 (Phase 3) | Mar 4, 2026 | Biontech, Bristol-Myers Squibb |
| NCT07291076 | Phase 1/Phase 2 (Phase 2) | Feb 9, 2026 | Biontech, Bristol-Myers Squibb |
| NCT07297212 | Phase 2 | Jan 31, 2026 | Biontech, Bristol-Myers Squibb |
| NCT07255404 | Phase 2 | Dec 31, 2025 | Biontech, Bristol-Myers Squibb |
| NCT07173751 | Phase 3 | Oct 30, 2025 | Biontech, Bristol-Myers Squibb |
| NCT07111520 | Phase 1/Phase 2 (Phase 2) | Sep 22, 2025 | Biontech, Suzhou Medilink Therapeutics Ltd. |
| NCT07147348 | Phase 1/Phase 2 (Phase 2) | Aug 27, 2025 | Biontech |
| NCT07070232 | Phase 1/Phase 2 (Phase 2) | Aug 12, 2025 | Biontech |
| NCT07079631 | Phase 1/Phase 2 (Phase 2) | Jul 18, 2025 | Biontech, Genmab |
| NCT06953089 | Phase 2 | Jul 18, 2025 | Biontech, DualityBio Inc. |
| NCT06892548 | Phase 1/Phase 2 (Phase 2) | May 2, 2025 | Biontech, Biotheus, DualityBio Inc. |
| NCT06827236 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2025 | Biontech, Biotheus, DualityBio Inc. |
| NCT06841055 | Phase 2 | Mar 31, 2025 | Biontech |
| NCT06712355 | Phase 3 | Dec 31, 2024 | Biontech, Biotheus |
| NCT06712316 | Phase 2/Phase 3 (Phase 3) | Dec 31, 2024 | Biontech, Biotheus |
| NCT06449222 | Phase 2 | Aug 26, 2024 | Biontech |
| NCT06449209 | Phase 2 | Aug 5, 2024 | Biontech |
Showing 19 of 19 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biontech | For profit | 19 | 14 | 2 | 2024 |
| Bristol-Myers Squibb | For profit | 7 | 4 | 2 | 2025 |
| Biotheus | For profit | 4 | 0 | 2 | 2024 |
| DualityBio Inc. | For profit | 3 | 1 | 1 | 2025 |
| Genmab | For profit | 1 | 0 | 1 | 2025 |
| Suzhou Medilink Therapeutics Ltd. | For profit | 1 | 0 | 1 | 2025 |
6 organizations
Page 1 / 1